| Literature DB >> 33927314 |
Marine Fauny1,2, Frank Verhoeven3, Edem Allado4,5,6, Eliane Albuisson7,8,9, Astrid Pinzano10,11, Caroline Morizot4, Isabelle Chary-Valckenaere4,10, Damien Loeuille4,10.
Abstract
To evaluate whether the risk of bone fragility on computed tomography (CT) (scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1)) is associated with the severity of spine structural involvement (mSASSS) in patients with ankylosing spondylitis (AS). This retrospective study included AS patients, followed from 2009 to 2017, who fulfilled the New York criteria and who underwent thoraco-abdomino-pelvic CT and radiography (spine, pelvis). The structural involvement was retained for mSASSS ≥ 2. The SBAC-L1 was measured in Hounsfield units (HU). A SBAC-L1 ≤ 145 HU was used to define patients at risk of vertebral fracture (VF). A total of 73 AS patients were included (mean age: 60.3 (± 10.7) years, 8 women (11%), mean disease duration: 24.6 years (± 13.9)). Sixty patients (82.2%) had a mSASSS ≥ 2 (mean score 20.7 (± 21.2)). The mean SBAC-L1 was 141.1 HU (± 45), 138.1 HU (± 44.8) and 154.8 HU (± 44.9) in the total, mSASSS ≥ 2 and mSASSS < 2 populations, respectively. Patients with bone bridges had lower SBAC-L1 than mSASSS ≥ 2 patients without ankylosis (p = 0.02) and more often SBAC-L1 ≤ 145 HU (73% vs 41.9%, p = 0.006). A SBAC-L1 ≤ 145 HU was not associated with structural spine involvement, but patients with bone bridges had significantly decreased SBAC-L1 and an increased probability of being under the fracture threshold.Entities:
Year: 2021 PMID: 33927314 PMCID: PMC8085178 DOI: 10.1038/s41598-021-88838-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographical, clinical characteristics and bone assessment on CT of the 73 AS patients according to spine structural involvement (mSASSS or vertebra ankylosis).
| All patients | mSASSS + | mSASSS - | |||||
|---|---|---|---|---|---|---|---|
| Bone bridge + | Bone bridge - | ||||||
| n = 37 | n = 23 | ||||||
| Age (n = 73) | 60.3 (60) | 62 (61) | 52.7 (57) | 0.493 | 62 (57.5–73) | 59 (53–67) | 0.88 |
| Men (n = 73) | 65 (89) | 53 (88.3) | 12 (92.3) | 0.677 | 34 (91.9) | 19 (82.6) | 0.276 |
| Smoker (n = 48) | 31 (42.5) | 25 (41.7) | 6 (46.2) | 0.5 | 17 (45.9) | 8 (34.8) | 0.931 |
| Alcool (n = 28) | 4 (5.48) | 4 (6.7) | 0 (0) | 0.678 | 4 (10.8) | 0 (0) | 0.160 |
| Disease duration (n = 71) | 24 (12–34) | 25 (13–35) | 15.5 (12–25.25) | 0.076 | 27 (13.75–35.75) | 24 (11–35) | 0.529 |
| BASFI (n = 58) | 43.5 (23.7) | 44.5 (22.2) | 41.2 (30.8) | 0.598 | 46.7 (22.2) | 42 (22.4) | 0.319 |
| BASDAI (n = 62) | 7.2 (10.5) | 7.1 (10.5) | 8.4 (11.3) | 1.0 | 7.2 (12.7) | 6.9 (7.3) | 0.236 |
| ASDAS (n = 21) | 3.4 (1.2) | 3.4 (0.9) | 3 (2.6) | 0.763 | 3.7 (1) | 2.81 (0.6) | |
| HLA B27 (n = 69) | 46 (63) | 39 (65) | 7 (53.8) | 0.276 | 26 (70.3) | 13 (56.5) | 0.075 |
| Biological inflammation CRP (n = 69) | 31 (42.5) | 28 (46.7) | 3 (23.1) | 0.079 | 18 (48.6) | 10 (43.5) | 0.415 |
| mSASSS on radiographs (n = 73) | 20.7 (21.2) | 25.1 (20.8) | 0 (0) | 37.2 (17.8) | 5.9 (4.2) | ||
| Corticosteroids (n = 49) | 7 (9.6) | 5 (8.3) | 2 (15.4) | 0.243 | 3 (8.1) | 2 (8.7) | 0.926 |
| NSAIDs (n = 51) | 49 (67.1) | 44 (73.3) | 5 (38.5) | 0.634 | 30 (81.1) | 14 (60.9) | |
| Proton Pomp Inhibitor (n = 15) | 15 (20.5) | 14 (23.3) | 1 (7.7) | / | 9 (24.3) | 5 (21.7) | / |
| TNF inhibitor (n = 43) | 43 (58.9) | 36 (60) | 7 (53.8) | / | 23 (62.2) | 13 (56.5) | / |
| Vitamin D and/or calcium (n = 73) | 18 (24.6) | 14 (23.3) | 4 (30.8) | 0.573 | 9 (24.3) | 5 (21.7) | 0.818 |
| Specific treatment for osteoporosis (n = 72) | 12 (16.4) | 9 (15) | 3 (23.1) | 0.493 | 8 (21.6) | 1 (4.3) | 0.063 |
| Mean (SD) in HU | 141.1 (45) | 138.1 (44.8) | 154.8 (44.9) | 0.239 | 123.96 (41.1) | 160.4 (41.9) | |
| Fracture threshold (145 HU) | 42 (57.5) | 36 (60) | 6 (46.2) | 0.325 | 27 (73) | 9 (39.1) | |
| Number of patients | 9 (12.3) | 8 (13.3) | 1 (7.7) | 0.575 | 5 (13.5) | 3 (13) | 0.958 |
| Number of fractures | 13 | 12 | 1 | 0.582 | 8 | 4 | 0.435 |
all data in bold are statiscally significant data (p<0.05)
AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CRP, C-reactive protein; HU, Hounsfield unit; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NSAIDs, Non-steroidal anti-inflammatory drugs; SBAC-L1, scanographic bone attenuation coefficient of the first lumbar vertebra; SD, standard deviation; TNF, tumour necrosis factor; VF, vertebral fracture.
Age in mSASSS + group and disease duration are in median (IQR), whereas age in general population, BASDAI, BASFI, ASDAS are in mean (± SD). In the comparisons, the Student’s t-test or the Mann–Whitney U test were used. For qualitative variables, the chi-square test with, if necessary, the exact calculation of Fisher was used. The risk α was established as 0.05.
mSASSS + was defined by a mSASSS ≥ 2, with the presence of at least one syndesmophyte.
Figure 2Spine structural lesions for each vertebra issued from mSASSS analysis.
Figure 3SBAC-L1 according the presence of VF.